Clinical Trial Finder

DISEASE CHARACTERISTICS:

• - Histologically or cytologically confirmed Glioblastoma Multiforme.

• - Subtotal resection or biopsy only of tumor.

• - Measurable tumor by MRI scan performed within two weeks prior to study entry.

• - Tumor must be at least 5 mm.

• - No brain stem tumor.

PATIENT CHARACTERISTICS: Age:

• - 18 and over.

Performance status:

• - Karnofsky 60-100% Life expectancy: - More than 4 months.

Hematopoietic:

• - WBC at least 1,500/mm^3.

• - Platelet count at least 50,000/mm^3.

• - Hemoglobin at least 10 g/dL.

Hepatic:

• - No hepatic failure.

• - Bilirubin no greater than 2.5 mg/dL.

• - SGOT and SGPT no greater than 5 times upper limit of normal.

Renal:

• - Creatinine no greater than 2.5 mg/dL.

• - No history of renal conditions that would contraindicate high dosages of sodium.

Cardiovascular:

• - No uncontrolled hypertension.

Other:

• - Not pregnant or nursing.

PRIOR CONCURRENT THERAPY: Biologic therapy:

• - No prior immunotherapy.

• - No concurrent immunomodulatory agents.

Chemotherapy:

• - No prior chemotherapy.

• - No concurrent antineoplastic agents.

Endocrine therapy:

• - Concurrent corticosteroids for cerebral edema allowed.

Radiotherapy:

• - No prior radiotherapy.

Surgery:

• - See Disease Characteristics.

- Recovered from any prior surgery

OVERVIEW: This is a single arm, open-label study in which adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme receive gradually escalating doses of intravenous Antineoplaston therapy (Atengenal + Astugenal) until the maximum tolerated dose is reached. Treatment continues for at least 12 months in the absence of disease progression or unacceptable toxicity. OBJECTIVES:

• - To determine the efficacy of Antineoplaston therapy in adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme, as measured by an objective response to therapy (complete response, partial response or stable disease).

• - To determine the safety and tolerance of Antineoplaston therapy in adults (≥ 18 years of age) with newly diagnosed Glioblastoma Multiforme.

• - To determine objective response, tumor size is measured utilizing MRI scans, which are performed every 8 weeks for the first two years, every 3 months for the third and fourth years, every 6 months for the 5th and sixth years, and annually thereafter.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued to this study.

Arms

Experimental: Antineoplaston therapy

Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Interventions

Drug: - Antineoplaston therapy (Atengenal + Astugenal)

Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.